跳至主要内容
临床试验/NCT00990782
NCT00990782已完成不适用

CEPELA I Trial: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment

The Cleveland Clinic2 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
93
试验地点
2
主要终点
Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy

研究概览

简要总结

This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.

详细描述

Patients undergoing radiofrequency ablation (RFA) therapy for atrial fibrillation, can sometimes experience insult or injury to the esophagus, due to the proximity of the esophagus to the RFA treatment area. This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptomatic patients with persistent atrial fibrillation selected for radiofrequency ablation
  • Adults aged 18 years and older
  • Patients able to give informed consent

排除标准

  • Patients under the age of 18
  • Patient unable to or unwilling to swallow the capsule endoscopes
  • Patients with cardiac pacemakers, implanted cardiac defibrillators or other implanted electro-medical devices
  • Pregnant or lactating females
  • Subjects with history of abdominal, pelvic, or bowel surgery within the past year

结局指标

主要结局

Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy

时间窗: 14 days

次要结局

  • Number of Participants With Capsule-identified Esophageal Injury Who Report Symptoms Post-RFA(14 Days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验